Compare Realty Income Corp (O) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs ResMed Inc. — how do they compare? Realty Income Corp trades at $54.18 (market cap $51.26B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and ResMed Inc. for 51 Days on average.
| O | RMD | |
|---|---|---|
Market Cap | $51.26B | $31.89B |
Volume | 12,300,266 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $277.88 |
52-Week Low | $53.35 | $182.82 |
Typical Hold Time | 127 Days | 51 Days |
Enterprise Value | $81.88B | $31.24B |
Dividend Yield | 6.01% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.18, up 1.56% today, but remains in a bearish technical trend with recent earnings misses and a high P/E of 39.54. Revenue grew to $5.75B in 2025, with a net income margin of 21.23%, but rising debt levels and negative cash flow projections for 2026 pose concerns. Analyst sentiment is mixed, with a consensus price target of $64.80, though technical indicators signal caution.
The stock offers a defensive dividend play with consistent payouts, but faces headwinds from rising interest rates and elevated valuation. Upside depends on earnings recovery and debt management, while risks include further technical weakness and macroeconomic pressure on REITs.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
